Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Limited-stage Mantle Cell Lymphoma: Real-world outcomes according to nodal vs. extranodal presentation

Sun-Hye Ko, Michael Crump, John Kuruvilla, David Hodgson, Danielle Rodin, Tomohiro Aoki, Sita Bhella, Robert Kridel, Vishal Kukreti, Nauman Malik, Abi Vijenthira, Chloe Yang, Anca Prica

Blood (2025) 146 (Supplement 1): 2769.

https://doi.org/10.1182/blood-2025-2769

Published: 2025

Journal Articles

Radiotherapy consolidation post-autologous stem cell transplant in Relapsed/Refractory aggressive non-Hodgkin lymphoma improves progression-free and overall survival in patients with partial but not complete metabolic response pre-transplant

Blood (2025) 146 (Supplement 1): 7188.

https://doi.org/10.1182/blood-2025-7188

Published: 2025

Journal Articles

Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy

Rintu Sharma, Pamella Paul, Harjot Singh Vohra, Eshetu Atenafu, John Kuruvilla, Michael Crump, Robert Kridel, Sita Bhella, Vishal Kukreti, Chloe Yang, Abi Vijenthira, Anca Prica, Christine Chen

Blood (2025) 146 (Supplement 1): 5505.

https://doi.org/10.1182/blood-2025-5505

Published: 2025

Journal Articles

Do chip mutations predict frailty and toxicity in transplant-eligible patients with multiple myeloma?

Steven Chun-Min Shih, Harjot Singh Vohra, Sahar Khan, Salman Basrai, Esther Masih-Khan, Anup Devasia, Donna Reece, Suzanne Trudel, Keith Stewart, Sita Bhella, Vishal Kukreti, Chloe Yang, Guido Lancman, Rodger Tiedemann, Anca Prica, Eugene Leung, Aaron Schimmer, Sagi Abelson, Christine Chen

Blood (2025) 146 (Supplement 1): 5773.

https://doi.org/10.1182/blood-2025-5773

Published: 2025

Journal Articles

Patient journey with axicabtagene ciloleucel for relapsed or refractory large B cell lymphoma in Canada: Manufacturing experience and impact of patient location to treatment centre

Sita Bhella, Isabelle Fleury, Christopher Lemieux, Sue ZJ Li, Lieven Billen, David Myers, Marie-Pierre Fontaine, Iwona Grzegorczyk-Manuel, Brad Du, Taryn Shuler, Natasha Kekre

Blood (2025) 146 (Supplement 1): 2730.

https://doi.org/10.1182/blood-2025-2730

Published: 2025

Journal Articles

Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)

Rintu Sharma, Esther Masih-Khan, Harjot Singh Vohra, Sita Bhella, Christine Chen, Chloe Yang, Guido Lancman, Keith Stewart, Vishal Kukreti, Vathany Kulasingam, Abir Khaled, Zac McDonald, Liqiang Yang, Arleigh McCurdy, Suzanne Trudel

Blood (2025) 146 (Supplement 1): 2250.

https://doi.org/10.1182/blood-2025-2250

Published: 2025

Journal Articles

Longitudinal assessments of simple frailty tools can help predict outcomes of patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy: A prospective pilot study at Princess Margaret Cancer Centre

Anca Prica, Antonette Pillainayagam, Manjula Maganti, Tiana Coley, Abi Vijenthira, Samantha Mayo, John Kuruvilla, Michael Crump, Sita Bhella, Robert Kridel, Vishal Kukreti, Chloe Yang, Shabbir Alibhai, Christine Chen

Blood (2025) 146 (Supplement 1): 4530.

https://doi.org/10.1182/blood-2025-4530

Published: 2025

Journal Articles

Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin

Anup Joseph Devasia, Olsen Chan, Harjot Vohra, Esther Masih-Khan, Chloe Yang, Sita Bhella, Rodger E Tiedemann, Vishal Kukreti, Christine I Chen, Keith Stewart, Donna Reece, Suzanne Trudel, Guido Lancman

Blood (2024) 144 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2024-209131

Published: 2024

Journal Articles

A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Tiana Kordbacheh, Anca Prica, Kelvin KW Chan, Mahmood Aminilari, Zharmaine Ante, Ning Liu, Inna Y Gong, Sita Bhella, Michael Crump, Abi Vijenthira, John Kuruvilla, Robert Kridel, Christine I Chen, Vishal Kukreti, Chloe Yang, Nauman Malik, David Hodgson, Danielle Rodin

Blood (2024) 144 (Supplement 1): 5134.

https://doi.org/10.1182/blood-2024-206375

Published: 2024

Journal Articles

Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis

Rintu Sharma, John Kuruvilla, Michael Crump, David Hodgson, Yangqing Deng, Abi Vijenthira, Vishal Kukreti, Robert Kridel, Rodger E Tiedemann, Sita Bhella, Chloe Yang, Anca Prica

Blood (2024) 144 (Supplement 1): 3082.

https://doi.org/10.1182/blood-2024-212184

Published: 2024

Journal Articles

Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma

Davidson Zhao, Victoria Shelton, Inna Gong, Juan Rangel-Patiño, Ting Liu, Michael Hong, Vanessa Murad, Ur Metser, Anca Prica, Vishal Kukreti, Sita Bhella, Abi Vijenthira, Michael Crump, John Kuruvilla, Bernard Lam, Robert Kridel

Blood (2024) 144 (Supplement 1): 1606.

https://doi.org/10.1182/blood-2024-199677

Published: 2024

Journal Articles

Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial

Rami Kotb, Darrell White, Sita Bhella, Arleigh McCurdy, Irwindeep Sandhu, Hira Mian, Julie Stakiw, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Donna Reece

Blood (2023) 142 (Supplement 1): 4751.

https://doi.org/10.1182/blood-2023-190168

Published: 2023

Journal Articles

Frailty in Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

Anca Prica, Tiana Coley, Rachel Aitken, Abi Vijenthira, Manjula Maganti, Samantha J Mayo, Christine I. Chen, John Kuruvilla, Michael Crump, Sita Bhella, Robert Kridel, Vishal Kukreti, Chloe Yang, Shabbir Alibhai

Blood (2022) 140 (Supplement 1): 8028–8029.

https://doi.org/10.1182/blood-2022-170204

Published: 2022

Journal Articles

Clinical Characteristics and Disease Outcomes in Primary Bone Lymphoma: Retrospective Study

Esther Bronwyn Ting, Sahar Khan, Manjula Maganti, Sita Bhella, Michael Crump, David C. Hodgson, Robert Kridel, Vishal Kukreti, John Kuruvilla, Danielle Rodin, Richard Tsang, Anca Prica

Blood (2022) 140 (Supplement 1): 3781–3782.

https://doi.org/10.1182/blood-2022-166118

Published: 2022

Journal Articles

Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma

Ashish Patel, Adam C. Smith, Esther Masih-Khan, Peace Samuel, Katherine Lajkosz, Sita Bhella, Christine I. Chen, Anca Prica, Donna E. Reece, A. Keith Stewart, Rodger E Tiedemann, Suzanne Trudel, Chloe Yang, Vishal Kukreti

Blood (2022) 140 (Supplement 1): 4354–4355.

https://doi.org/10.1182/blood-2022-167113

Published: 2022

Journal Articles

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

Salman Alharbi, Maria Agustina Perusini, Sita Bhella, Mark D. Minden, Dawn Maze, Vikas Gupta, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Steven M. Chan, Aniket Bankar, Marta B. Davidson, Guillaume Richard-Carpentier, Jad Sibai, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3187–3188.

https://doi.org/10.1182/blood-2022-168662

Published: 2022

Journal Articles

Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Anup Joseph Devasia, Sahar Khan, Harminder K Paul, Frédéric Larose, Eshetu G. Atenafu, Donna E. Reece, Suzanne Trudel, A. Keith Stewart, Sita Bhella, Vishal Kukreti, Chloe Yang, Rodger E Tiedemann, Anca Prica, Monica Monchis, Eugene Leung, Susan Jomah, Zubaida Mohamed, Christine Chen

Blood (2022) 140 (Supplement 1): 10043–10044.

https://doi.org/10.1182/blood-2022-170681

Published: 2022

Journal Articles

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Anca Prica, Vinita Dhir, Rachel Aitken, Harminder K Paul, Osvaldo Espin-Garcia, Sita Bhella, Christine I. Chen, Michael Crump, Robert Kridel, Vishal Kukreti, John Kuruvilla, Donna E. Reece, Rodger E Tiedemann, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 3055.

https://doi.org/10.1182/blood-2021-153120

Published: 2021

Journal Articles

Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size

Alfredo De La Torre, Eshetu G Atenafu, Adam C. Smith, Vishal Kukreti, Anca Prica, Sita Bhella, Donna E. Reece, Rodger E Tiedemann, Suzanne Trudel, Christine I. Chen

Blood (2021) 138 (Supplement 1): 460.

https://doi.org/10.1182/blood-2021-153011

Published: 2021

Journal Articles

Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume

Ho-Young Yhim, Yael Eshet, Ur Metser, Katherine Lajkosz, Matthew Cooper, Anca Prica, Vishal Kukreti, Sita Bhella, Noemie Lang, Wei Xu, Danielle Rodin, David Hodgson, Richard Tsang, Michael Crump, John Kuruvilla, Robert Kridel

Blood (2021) 138 (Supplement 1): 1383.

https://doi.org/10.1182/blood-2021-148942

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Limited-stage Mantle Cell Lymphoma: Real-world outcomes according to nodal vs. extranodal presentation

Radiotherapy consolidation post-autologous stem cell transplant in Relapsed/Refractory aggressive non-Hodgkin lymphoma improves progression-free and overall survival in patients with partial but not complete metabolic response pre-transplant

Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy

Do chip mutations predict frailty and toxicity in transplant-eligible patients with multiple myeloma?

Patient journey with axicabtagene ciloleucel for relapsed or refractory large B cell lymphoma in Canada: Manufacturing experience and impact of patient location to treatment centre

Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)

Longitudinal assessments of simple frailty tools can help predict outcomes of patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy: A prospective pilot study at Princess Margaret Cancer Centre

Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin

A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis

Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma

Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial

Frailty in Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

Clinical Characteristics and Disease Outcomes in Primary Bone Lymphoma: Retrospective Study

Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size

Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only